カテゴリー： Market Monitor Global, 世界, 医療/バイオ

組換えリツキシマブ注射剤のグローバル市場展望 2023年-2029年：100mg、500mg

◆英語タイトル：Recombinant Rituximab Injection Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23DC14454）◆商品コード：MMG23DC14454
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年12月（※2025年版があります。お問い合わせください。）
◆ページ数：101
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥468,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥608,400見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥702,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の組換えリツキシマブ注射剤市場規模と予測を収録しています。・世界の組換えリツキシマブ注射剤市場：売上、2018年-2023年、2024年-2029年
・世界の組換えリツキシマブ注射剤市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の組換えリツキシマブ注射剤市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「100mg」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

組換えリツキシマブ注射剤のグローバル主要企業は、Roche、 Pfizer、 Amgen、 Celltrion Healthcare、 Henlius、 Innovent Biologicsなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、組換えリツキシマブ注射剤のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の組換えリツキシマブ注射剤市場：タイプ別、2018年-2023年、2024年-2029年
世界の組換えリツキシマブ注射剤市場：タイプ別市場シェア、2022年
・100mg、500mg

世界の組換えリツキシマブ注射剤市場：用途別、2018年-2023年、2024年-2029年
世界の組換えリツキシマブ注射剤市場：用途別市場シェア、2022年
・病院、診療所、その他

世界の組換えリツキシマブ注射剤市場：地域・国別、2018年-2023年、2024年-2029年
世界の組換えリツキシマブ注射剤市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における組換えリツキシマブ注射剤のグローバル売上、2018年-2023年
・主要企業における組換えリツキシマブ注射剤のグローバル売上シェア、2022年
・主要企業における組換えリツキシマブ注射剤のグローバル販売量、2018年-2023年
・主要企業における組換えリツキシマブ注射剤のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Roche、 Pfizer、 Amgen、 Celltrion Healthcare、 Henlius、 Innovent Biologics

*************************************************************

・調査・分析レポートの概要
組換えリツキシマブ注射剤市場の定義
市場セグメント
世界の組換えリツキシマブ注射剤市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の組換えリツキシマブ注射剤市場規模
世界の組換えリツキシマブ注射剤市場規模：2022年 VS 2029年
世界の組換えリツキシマブ注射剤市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの組換えリツキシマブ注射剤の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の組換えリツキシマブ注射剤製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：100mg、500mg
組換えリツキシマブ注射剤のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、診療所、その他
組換えリツキシマブ注射剤の用途別グローバル売上・予測

・地域別市場分析
地域別組換えリツキシマブ注射剤市場規模 2022年と2029年
地域別組換えリツキシマブ注射剤売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Roche、 Pfizer、 Amgen、 Celltrion Healthcare、 Henlius、 Innovent Biologics
...

This research report provides a comprehensive analysis of the Recombinant Rituximab Injection market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Recombinant Rituximab Injection market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Recombinant Rituximab Injection, challenges faced by the industry, and potential opportunities for market players.
The global Recombinant Rituximab Injection market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Recombinant Rituximab Injection market presents opportunities for various stakeholders, including Hospital, Clinic. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Recombinant Rituximab Injection market. Additionally, the growing consumer demand present avenues for market expansion.
The global Recombinant Rituximab Injection market was valued at US$ 1277.1 million in 2022 and is projected to reach US$ 1716.1 million by 2029, at a CAGR of 4.3% during the forecast period.
Recombinant Rituximab Injection is a significant biopharmaceutical product widely used for the treatment of various autoimmune diseases and malignant tumors. The market for this product is substantial and continuously growing due to the increasing demand for healthcare. In the future, it is expected that this field will continue to evolve, with specific uses of Rituximab Injection potentially expanding to include the treatment of more autoimmune diseases, presenting additional business opportunities in the biopharmaceutical industry.
Key Features:
The research report on the Recombinant Rituximab Injection market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Recombinant Rituximab Injection market.
Market Overview: The report provides a comprehensive overview of the Recombinant Rituximab Injection market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., 100mg, 500mg), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Recombinant Rituximab Injection market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Recombinant Rituximab Injection market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Recombinant Rituximab Injection market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Recombinant Rituximab Injection market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Recombinant Rituximab Injection market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Recombinant Rituximab Injection market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Recombinant Rituximab Injection, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Recombinant Rituximab Injection market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Recombinant Rituximab Injection market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
100mg
500mg
Market segment by Application
Hospital
Clinic
Others
Global Recombinant Rituximab Injection Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Roche
Pfizer
Amgen
Celltrion Healthcare
Henlius
Innovent Biologics
Outline of Major Chapters:
Chapter 1: Introduces the definition of Recombinant Rituximab Injection, market overview.
Chapter 2: Global Recombinant Rituximab Injection market size in revenue and volume.
Chapter 3: Detailed analysis of Recombinant Rituximab Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Recombinant Rituximab Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Recombinant Rituximab Injection capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Recombinant Rituximab Injection Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Recombinant Rituximab Injection Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Recombinant Rituximab Injection Overall Market Size
2.1 Global Recombinant Rituximab Injection Market Size: 2022 VS 2029
2.2 Global Recombinant Rituximab Injection Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Recombinant Rituximab Injection Sales: 2018-2029
3 Company Landscape
3.1 Top Recombinant Rituximab Injection Players in Global Market
3.2 Top Global Recombinant Rituximab Injection Companies Ranked by Revenue
3.3 Global Recombinant Rituximab Injection Revenue by Companies
3.4 Global Recombinant Rituximab Injection Sales by Companies
3.5 Global Recombinant Rituximab Injection Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Recombinant Rituximab Injection Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Recombinant Rituximab Injection Product Type
3.8 Tier 1, Tier 2 and Tier 3 Recombinant Rituximab Injection Players in Global Market
3.8.1 List of Global Tier 1 Recombinant Rituximab Injection Companies
3.8.2 List of Global Tier 2 and Tier 3 Recombinant Rituximab Injection Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Recombinant Rituximab Injection Market Size Markets, 2022 & 2029
4.1.2 100mg
4.1.3 500mg
4.2 By Type – Global Recombinant Rituximab Injection Revenue & Forecasts
4.2.1 By Type – Global Recombinant Rituximab Injection Revenue, 2018-2023
4.2.2 By Type – Global Recombinant Rituximab Injection Revenue, 2024-2029
4.2.3 By Type – Global Recombinant Rituximab Injection Revenue Market Share, 2018-2029
4.3 By Type – Global Recombinant Rituximab Injection Sales & Forecasts
4.3.1 By Type – Global Recombinant Rituximab Injection Sales, 2018-2023
4.3.2 By Type – Global Recombinant Rituximab Injection Sales, 2024-2029
4.3.3 By Type – Global Recombinant Rituximab Injection Sales Market Share, 2018-2029
4.4 By Type – Global Recombinant Rituximab Injection Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Recombinant Rituximab Injection Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Others
5.2 By Application – Global Recombinant Rituximab Injection Revenue & Forecasts
5.2.1 By Application – Global Recombinant Rituximab Injection Revenue, 2018-2023
5.2.2 By Application – Global Recombinant Rituximab Injection Revenue, 2024-2029
5.2.3 By Application – Global Recombinant Rituximab Injection Revenue Market Share, 2018-2029
5.3 By Application – Global Recombinant Rituximab Injection Sales & Forecasts
5.3.1 By Application – Global Recombinant Rituximab Injection Sales, 2018-2023
5.3.2 By Application – Global Recombinant Rituximab Injection Sales, 2024-2029
5.3.3 By Application – Global Recombinant Rituximab Injection Sales Market Share, 2018-2029
5.4 By Application – Global Recombinant Rituximab Injection Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Recombinant Rituximab Injection Market Size, 2022 & 2029
6.2 By Region – Global Recombinant Rituximab Injection Revenue & Forecasts
6.2.1 By Region – Global Recombinant Rituximab Injection Revenue, 2018-2023
6.2.2 By Region – Global Recombinant Rituximab Injection Revenue, 2024-2029
6.2.3 By Region – Global Recombinant Rituximab Injection Revenue Market Share, 2018-2029
6.3 By Region – Global Recombinant Rituximab Injection Sales & Forecasts
6.3.1 By Region – Global Recombinant Rituximab Injection Sales, 2018-2023
6.3.2 By Region – Global Recombinant Rituximab Injection Sales, 2024-2029
6.3.3 By Region – Global Recombinant Rituximab Injection Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Recombinant Rituximab Injection Revenue, 2018-2029
6.4.2 By Country – North America Recombinant Rituximab Injection Sales, 2018-2029
6.4.3 US Recombinant Rituximab Injection Market Size, 2018-2029
6.4.4 Canada Recombinant Rituximab Injection Market Size, 2018-2029
6.4.5 Mexico Recombinant Rituximab Injection Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Recombinant Rituximab Injection Revenue, 2018-2029
6.5.2 By Country – Europe Recombinant Rituximab Injection Sales, 2018-2029
6.5.3 Germany Recombinant Rituximab Injection Market Size, 2018-2029
6.5.4 France Recombinant Rituximab Injection Market Size, 2018-2029
6.5.5 U.K. Recombinant Rituximab Injection Market Size, 2018-2029
6.5.6 Italy Recombinant Rituximab Injection Market Size, 2018-2029
6.5.7 Russia Recombinant Rituximab Injection Market Size, 2018-2029
6.5.8 Nordic Countries Recombinant Rituximab Injection Market Size, 2018-2029
6.5.9 Benelux Recombinant Rituximab Injection Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Recombinant Rituximab Injection Revenue, 2018-2029
6.6.2 By Region – Asia Recombinant Rituximab Injection Sales, 2018-2029
6.6.3 China Recombinant Rituximab Injection Market Size, 2018-2029
6.6.4 Japan Recombinant Rituximab Injection Market Size, 2018-2029
6.6.5 South Korea Recombinant Rituximab Injection Market Size, 2018-2029
6.6.6 Southeast Asia Recombinant Rituximab Injection Market Size, 2018-2029
6.6.7 India Recombinant Rituximab Injection Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Recombinant Rituximab Injection Revenue, 2018-2029
6.7.2 By Country – South America Recombinant Rituximab Injection Sales, 2018-2029
6.7.3 Brazil Recombinant Rituximab Injection Market Size, 2018-2029
6.7.4 Argentina Recombinant Rituximab Injection Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Recombinant Rituximab Injection Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Recombinant Rituximab Injection Sales, 2018-2029
6.8.3 Turkey Recombinant Rituximab Injection Market Size, 2018-2029
6.8.4 Israel Recombinant Rituximab Injection Market Size, 2018-2029
6.8.5 Saudi Arabia Recombinant Rituximab Injection Market Size, 2018-2029
6.8.6 UAE Recombinant Rituximab Injection Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Roche
7.1.1 Roche Company Summary
7.1.2 Roche Business Overview
7.1.3 Roche Recombinant Rituximab Injection Major Product Offerings
7.1.4 Roche Recombinant Rituximab Injection Sales and Revenue in Global (2018-2023)
7.1.5 Roche Key News & Latest Developments
7.2 Pfizer
7.2.1 Pfizer Company Summary
7.2.2 Pfizer Business Overview
7.2.3 Pfizer Recombinant Rituximab Injection Major Product Offerings
7.2.4 Pfizer Recombinant Rituximab Injection Sales and Revenue in Global (2018-2023)
7.2.5 Pfizer Key News & Latest Developments
7.3 Amgen
7.3.1 Amgen Company Summary
7.3.2 Amgen Business Overview
7.3.3 Amgen Recombinant Rituximab Injection Major Product Offerings
7.3.4 Amgen Recombinant Rituximab Injection Sales and Revenue in Global (2018-2023)
7.3.5 Amgen Key News & Latest Developments
7.4 Celltrion Healthcare
7.4.1 Celltrion Healthcare Company Summary
7.4.2 Celltrion Healthcare Business Overview
7.4.3 Celltrion Healthcare Recombinant Rituximab Injection Major Product Offerings
7.4.4 Celltrion Healthcare Recombinant Rituximab Injection Sales and Revenue in Global (2018-2023)
7.4.5 Celltrion Healthcare Key News & Latest Developments
7.5 Henlius
7.5.1 Henlius Company Summary
7.5.2 Henlius Business Overview
7.5.3 Henlius Recombinant Rituximab Injection Major Product Offerings
7.5.4 Henlius Recombinant Rituximab Injection Sales and Revenue in Global (2018-2023)
7.5.5 Henlius Key News & Latest Developments
7.6 Innovent Biologics
7.6.1 Innovent Biologics Company Summary
7.6.2 Innovent Biologics Business Overview
7.6.3 Innovent Biologics Recombinant Rituximab Injection Major Product Offerings
7.6.4 Innovent Biologics Recombinant Rituximab Injection Sales and Revenue in Global (2018-2023)
7.6.5 Innovent Biologics Key News & Latest Developments
8 Global Recombinant Rituximab Injection Production Capacity, Analysis
8.1 Global Recombinant Rituximab Injection Production Capacity, 2018-2029
8.2 Recombinant Rituximab Injection Production Capacity of Key Manufacturers in Global Market
8.3 Global Recombinant Rituximab Injection Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Recombinant Rituximab Injection Supply Chain Analysis
10.1 Recombinant Rituximab Injection Industry Value Chain
10.2 Recombinant Rituximab Injection Upstream Market
10.3 Recombinant Rituximab Injection Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Recombinant Rituximab Injection Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Recombinant Rituximab Injection in Global Market
Table 2. Top Recombinant Rituximab Injection Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Recombinant Rituximab Injection Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Recombinant Rituximab Injection Revenue Share by Companies, 2018-2023
Table 5. Global Recombinant Rituximab Injection Sales by Companies, (K Units), 2018-2023
Table 6. Global Recombinant Rituximab Injection Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Recombinant Rituximab Injection Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Recombinant Rituximab Injection Product Type
Table 9. List of Global Tier 1 Recombinant Rituximab Injection Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Recombinant Rituximab Injection Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Recombinant Rituximab Injection Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Recombinant Rituximab Injection Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Recombinant Rituximab Injection Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Recombinant Rituximab Injection Sales (K Units), 2018-2023
Table 15. By Type - Global Recombinant Rituximab Injection Sales (K Units), 2024-2029
Table 16. By Application – Global Recombinant Rituximab Injection Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Recombinant Rituximab Injection Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Recombinant Rituximab Injection Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Recombinant Rituximab Injection Sales (K Units), 2018-2023
Table 20. By Application - Global Recombinant Rituximab Injection Sales (K Units), 2024-2029
Table 21. By Region – Global Recombinant Rituximab Injection Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Recombinant Rituximab Injection Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Recombinant Rituximab Injection Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Recombinant Rituximab Injection Sales (K Units), 2018-2023
Table 25. By Region - Global Recombinant Rituximab Injection Sales (K Units), 2024-2029
Table 26. By Country - North America Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Recombinant Rituximab Injection Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Recombinant Rituximab Injection Sales, (K Units), 2018-2023
Table 29. By Country - North America Recombinant Rituximab Injection Sales, (K Units), 2024-2029
Table 30. By Country - Europe Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Recombinant Rituximab Injection Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Recombinant Rituximab Injection Sales, (K Units), 2018-2023
Table 33. By Country - Europe Recombinant Rituximab Injection Sales, (K Units), 2024-2029
Table 34. By Region - Asia Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Recombinant Rituximab Injection Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Recombinant Rituximab Injection Sales, (K Units), 2018-2023
Table 37. By Region - Asia Recombinant Rituximab Injection Sales, (K Units), 2024-2029
Table 38. By Country - South America Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Recombinant Rituximab Injection Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Recombinant Rituximab Injection Sales, (K Units), 2018-2023
Table 41. By Country - South America Recombinant Rituximab Injection Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Recombinant Rituximab Injection Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Recombinant Rituximab Injection Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Recombinant Rituximab Injection Sales, (K Units), 2024-2029
Table 46. Roche Company Summary
Table 47. Roche Recombinant Rituximab Injection Product Offerings
Table 48. Roche Recombinant Rituximab Injection Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. Roche Key News & Latest Developments
Table 50. Pfizer Company Summary
Table 51. Pfizer Recombinant Rituximab Injection Product Offerings
Table 52. Pfizer Recombinant Rituximab Injection Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. Pfizer Key News & Latest Developments
Table 54. Amgen Company Summary
Table 55. Amgen Recombinant Rituximab Injection Product Offerings
Table 56. Amgen Recombinant Rituximab Injection Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. Amgen Key News & Latest Developments
Table 58. Celltrion Healthcare Company Summary
Table 59. Celltrion Healthcare Recombinant Rituximab Injection Product Offerings
Table 60. Celltrion Healthcare Recombinant Rituximab Injection Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. Celltrion Healthcare Key News & Latest Developments
Table 62. Henlius Company Summary
Table 63. Henlius Recombinant Rituximab Injection Product Offerings
Table 64. Henlius Recombinant Rituximab Injection Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. Henlius Key News & Latest Developments
Table 66. Innovent Biologics Company Summary
Table 67. Innovent Biologics Recombinant Rituximab Injection Product Offerings
Table 68. Innovent Biologics Recombinant Rituximab Injection Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. Innovent Biologics Key News & Latest Developments
Table 70. Recombinant Rituximab Injection Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 71. Global Recombinant Rituximab Injection Capacity Market Share of Key Manufacturers, 2021-2023
Table 72. Global Recombinant Rituximab Injection Production by Region, 2018-2023 (K Units)
Table 73. Global Recombinant Rituximab Injection Production by Region, 2024-2029 (K Units)
Table 74. Recombinant Rituximab Injection Market Opportunities & Trends in Global Market
Table 75. Recombinant Rituximab Injection Market Drivers in Global Market
Table 76. Recombinant Rituximab Injection Market Restraints in Global Market
Table 77. Recombinant Rituximab Injection Raw Materials
Table 78. Recombinant Rituximab Injection Raw Materials Suppliers in Global Market
Table 79. Typical Recombinant Rituximab Injection Downstream
Table 80. Recombinant Rituximab Injection Downstream Clients in Global Market
Table 81. Recombinant Rituximab Injection Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Recombinant Rituximab Injection Segment by Type in 2022
Figure 2. Recombinant Rituximab Injection Segment by Application in 2022
Figure 3. Global Recombinant Rituximab Injection Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Recombinant Rituximab Injection Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Recombinant Rituximab Injection Revenue, 2018-2029 (US$, Mn)
Figure 7. Recombinant Rituximab Injection Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Recombinant Rituximab Injection Revenue in 2022
Figure 9. By Type - Global Recombinant Rituximab Injection Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Recombinant Rituximab Injection Revenue Market Share, 2018-2029
Figure 11. By Type - Global Recombinant Rituximab Injection Sales Market Share, 2018-2029
Figure 12. By Type - Global Recombinant Rituximab Injection Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Recombinant Rituximab Injection Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Recombinant Rituximab Injection Revenue Market Share, 2018-2029
Figure 15. By Application - Global Recombinant Rituximab Injection Sales Market Share, 2018-2029
Figure 16. By Application - Global Recombinant Rituximab Injection Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Recombinant Rituximab Injection Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Recombinant Rituximab Injection Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Recombinant Rituximab Injection Revenue Market Share, 2018-2029
Figure 20. By Region - Global Recombinant Rituximab Injection Sales Market Share, 2018-2029
Figure 21. By Country - North America Recombinant Rituximab Injection Revenue Market Share, 2018-2029
Figure 22. By Country - North America Recombinant Rituximab Injection Sales Market Share, 2018-2029
Figure 23. US Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Recombinant Rituximab Injection Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Recombinant Rituximab Injection Sales Market Share, 2018-2029
Figure 28. Germany Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2029
Figure 29. France Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Recombinant Rituximab Injection Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Recombinant Rituximab Injection Sales Market Share, 2018-2029
Figure 37. China Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2029
Figure 41. India Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Recombinant Rituximab Injection Revenue Market Share, 2018-2029
Figure 43. By Country - South America Recombinant Rituximab Injection Sales Market Share, 2018-2029
Figure 44. Brazil Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Recombinant Rituximab Injection Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Recombinant Rituximab Injection Sales Market Share, 2018-2029
Figure 48. Turkey Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Recombinant Rituximab Injection Revenue, (US$, Mn), 2018-2029
Figure 52. Global Recombinant Rituximab Injection Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Recombinant Rituximab Injection by Region, 2022 VS 2029
Figure 54. Recombinant Rituximab Injection Industry Value Chain
Figure 55. Marketing Channels

※参考情報

組換えリツキシマブ注射剤は、がんや自己免疫疾患の治療に用いられる生物学的製剤であり、特にB細胞に発現する抗原CD20を標的とするモノクローナル抗体です。リツキシマブは初めて開発された抗CD20抗体の一つであり、主に悪性リンパ腫や慢性リンパ性白血病、特定の自己免疫疾患において効果を発揮します。本稿では、組換えリツキシマブ注射剤の定義、特徴、種類、用途、関連技術について詳述いたします。

組換えリツキシマブ注射剤の定義は、DNA技術を用いて培養細胞から生成されたリツキシマブを含む注射用製剤であるという点にあります。この製剤は、ヒトのT細胞やB細胞を標的にし、特にB細胞の除去を促進します。これにより、類似の状況下で過剰に増殖するB細胞の制御が可能になります。組換え技術を用いることで、製品の純度や活性を高めつつ、効率的に生産することができます。

組換えリツキシマブの特徴の一つは、その特異的な標的性です。CD20抗原はB細胞の表面に存在する分子であり、正常なB細胞と異常増殖したB細胞の両方に発現しています。このため、リツキシマブを用いることで、がん細胞のみならず、自己免疫疾患に関連する異常なB細胞も効果的に排除することが可能です。また、リツキシマブは細胞傷害性T細胞の誘導を促進し、抗体依存性細胞傷害（ADCC）を活性化させることで治療効果を高めます。

さらに、組換えリツキシマブにはいくつかの類似製品が存在します。これらは「バイオシミラー」と呼ばれ、元のリツキシマブと同等の効果を持ちながら、製造プロセスやコストにおいて異なる特性を持つ場合があります。バイオシミラーの開発は、医療費の削減や、患者への治療選択肢の拡大に寄与することが期待されています。

組換えリツキシマブ注射剤の主要な用途としては、主に以下の疾患が挙げられます。第一に、非ホジキンリンパ腫（NHL）やホジキンリンパ腫といった血液のがんにおける治療があります。これらの疾患においては、リツキシマブ単独、もしくは他の化学療法薬と併用して使用されます。また、慢性リンパ性白血病（CLL）、自己免疫疾患としては全身性エリテマトーデス（SLE）や関節リウマチにおける治療にも利用されています。

組換えリツキシマブの適用は、従来の化学療法に比べて副作用が少ないことが特徴です。化学療法では正常細胞も攻撃されるため、広範囲な副作用が生じることがありますが、リツキシマブは特定のB細胞に対して選択的に作用することから、副作用が軽減される傾向があります。それでも、副作用が全くないわけではなく、特に感染症のリスクが増加することが知られています。

関連技術としては、後発医薬品やバイオシミラーの開発が急速に進んでいます。これにより、リツキシマブのアクセスが広がり、患者にとっての治療選択肢が増えることが期待されています。また、生物製剤の製造過程において、精密な定量分析や安全性試験が行われることが求められています。これにより、製品の効果と安全性が担保されるようになっています。

製薬業界では、個別化医療の導入が進んでおり、組換えリツキシマブもその一環として、患者の遺伝的背景や病状に応じた治療アプローチが模索されています。特にバイオマーカーの利用により、リツキシマブ治療に対する反応が良好な患者を特定し、より効果的な治療戦略を立てることが可能になるでしょう。

最後に、リツキシマブの治療においては、医療者と患者とのコミュニケーションが重要です。治療効果や副作用、治療スケジュールに関する情報を適切に伝えることは、患者の治療への理解を深め、治療の遵守を促進する要素となります。これにより、治療成績の向上が期待されます。

以上のように、組換えリツキシマブ注射剤は、特定のがんや自己免疫疾患の治療において重要な役割を果たす生物製剤です。今後の研究や技術の進展により、より多くの患者に利益をもたらすことを期待しています。


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 組換えリツキシマブ注射剤のグローバル市場展望 2023年-2029年：100mg、500mg(Recombinant Rituximab Injection Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • セファランチンのグローバル市場2023年：20mg、50mg、100mg、500mg、1g
  • リツキサンのグローバル市場2025年：企業・地域・タイプ・用途別分析
  • リツキシマブ医薬品の世界市場見通し2023年-2029年
  • リツキシマブの世界市場見通し2023年-2029年
  • 長時間作用型遺伝子組換えヒトエリスロポエチンのグローバル市場展望 2023年-2029年：エポエチン-アルファ、エポエチン-ベータ、ダルベポエチン-アルファ、その他

    • ◆H&Iグローバルリサーチのお客様（例）◆